Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers

Raimundo Coutinho Jr1, Maria Fernanda Rios Grassi1,2*, Ana Beatriz Korngold1, Viviana Nilla Olavarria2, Bernardo Galvão-Castro1,2 and Rita Elizabeth Mascarenhas1,2

Abstract
Background: High HTLV-1 proviral load (PVL) is mainly found in infected individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, one third of asymptomatic carriers may have high PVL. This study aimed to evaluate the impact of PVL in the activation of T lymphocytes of asymptomatic individuals infected with HTLV-1.

Methods: Membrane activation markers (CD25+, CD28+, CD45RO+, CD69+, CD62L+, HLA-DR+), FoxP3+ and intracellular IFN-γ expression were evaluated on both CD4+ and CD8+ T-lymphocytes from asymptomatic carriers with PVL ≥ and < 1% of infected cells, using flow cytometry. HTLV-1 proviral load was determined using real-time PCR.

Results: Asymptomatic carriers with PVL ≥ 1% presented a higher frequency of CD4+CD25+CD45RO+ (13.2% vs. 4%, p = 0.02), CD4+HLA-DR+ (18% vs. 8.3%, p = 0.01) and CD4+IFN-γ+ (4.5%; 1%, p = 0.01) T-cells, than healthy donors. HTLV-1 PVL was directly correlated with the proportion of CD4+CD25+CD45RO+ T-cells (R = 0.7, p = 0.003). Moreover, a significant increase in the proportion of CD4+FoxP3+ T-cells was observed in HTLV-1-infected individuals, compared to healthy donors.

Conclusion: HTLV-1 PVL is associated with activation of both CD4+ and CD8+ T-lymphocytes in asymptomatic individuals. Prospective studies should be conducted to evaluate whether asymptomatic individuals with higher PVL and high immune activation are more prone to developing HTLV-1-associated diseases.

Keywords: HTLV-1, Proviral load, Asymptomatic, Activation

Background
The human T-lymphotropic virus type 1 (HTLV-1) was the first retrovirus known to cause disease in humans, initially isolated from the lymphocytes of a patient with cutaneous T-cell lymphoma in 1980 [1]. An estimated 10 to 20 million individuals are currently infected with HTLV-1 worldwide, mostly clustered in Japan, the Caribbean, Africa, and Latin America, with Brazil having the highest number of infected individuals [2]. This virus is recognized as the etiologic agent of HTLV-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) [3,4] and adult T-cell leukemia/lymphoma (ATL) [5], which affect less than 5% of all infected individuals, and occasionally causes HTLV-associated uveitis (HAU) [6] and infective dermatitis in children [7]. Other infectious diseases, such as strongyloidiasis [8] and tuberculosis [9,10], have also been described at a higher prevalence in patients infected with HTLV-1.

The association with these infectious diseases suggests that HTLV-1 may impair the host immune response, possibly leading to immunosuppression. Similar to the human immunodeficiency virus (HIV), HTLV-1 also integrates its genome into host cells, thereby establishing a persistent chronic infection. While HIV induces a potent immunodepression by destroying CD4+ T-cells, HTLV-1 promotes the spontaneous proliferation of CD4+ and CD8+ T-cell subsets, as well as NK cells [11-13].
HTLV-1-infected individuals frequently present immunological abnormalities, such as increased inflammatory cytokine production and T-lymphocyte activation, as well as a reduced lymphoproliferative response to recall antigens in vitro [13,14]. Moreover, immune system activation occurs more frequently and with greater intensity in individuals with HAM/TSP [14,15]. These individuals often present alterations in regulatory T-cells [16,17].

In the HIV infection, the plasmatic viral load is positively correlated with the intensity of T-cell activation, as well as the destruction of CD4+ T-lymphocytes and a progression to AIDS [18]. The general immune activation and exhaustion of immune system caused by HIV play also an important role in the immunodepression observed in AIDS patients [19]. By contrast, HTLV-1 proviral load (PVL) is not widely recognized as a biomarker to predict HTLV-associated disease evolution. HTLV-1 PVL is considered low if the proportion of infected PBMCs is lower than 1%, and high if greater than 5% [20]. High PVLs are commonly found in individuals with HAM/TSP [21,22], infective dermatitis [23] and Keratoconjunctivitis sicca [24]. However, in some cases, asymptomatic individuals may have high PVLs and exhibit an exacerbated inflammatory response [14,22]. To investigate the association between PVL and immune system activation, the present study evaluated the phenotypic profile of CD4+ and CD8+ T-cells in asymptomatic individuals infected with HTLV-1.

**Methods**

**Subjects**

Fifty seven asymptomatic HTLV-1-infected subjects were sequentially selected from the Bahiana School of Medicine and Public Health HTLV reference center (Salvador, Bahia, Brazil). They were included if evaluated neurologic examination was normal and had no clinical complaints. Exclusion criteria were co-infection with HIV and/or HCV, as well as other HTLV-1-associated diseases, such as infective dermatitis, uveitis, ATL. Eleven laboratory staff volunteered as non-infected controls. All samples were screened for HTLV-1/2 antibodies by enzyme-linked immunosorbent assay (ELISA) (Ab-Capture ELISA Test System – Ortho-Clinical Diagnostics, Inc., Raritan, New Jersey), and positive results were confirmed by Western Blot (HTLV Blot 2.4, Genelabs Technologies, Singapore). The number of evaluated in the immunological assays was as follow: spontaneous proliferation n = 28 HTLV-1-infected individuals, activation markers on CD4 and CD8+ T-subsets n = 10 and CD4+FoxP3+ n = 15 HTLV-1-infected individuals and 5 uninfected controls). This study was approved by the Ethical Committee of the Oswaldo Cruz Foundation (FIOCRUZ). Informed written consent was obtained from all enrolled individuals and the FIOCRUZ Institutional Review Board approved this study.

**Proliferation assay**

Blood samples were collected from all study subjects in heparin tubes and peripheral blood mononuclear cells (PBMC) were isolated using a ficoll-paque plus density gradient centrifuge (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Cultures of 10^5 PBMCs were incubated in triplicate for five days (37°C, 5% CO2) in RPMI-1640 medium (Sigma Chemical Co., St. Louis, MO, USA) supplemented with 2 mM L-glutamine, 1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 g/ml streptomycin and pooled human AB serum (10%) (Sigma). On the last day of incubation, cells were pulsed overnight with 1 μCi [3H]thymidine (specific activity, 2 Ci/mmol; ICN, Costa Mesa, CA). Incorporated [3H] thymidine was measured in terms of mean counts per minute (CPM) using β-radiation counter (MATRIX 9600 direct beta counter; Packard). Spontaneous proliferation of PBMCs was considered when a mean CPM value ≥ 500 due in triplicates (i.e., three times the mean counts per minute measured in uninfected control cells) was obtained.

**Flow cytometry**

50 μl of whole blood was incubated for 15 min at room temperature with anti-CD4 (BD Pharmingen Technical) and the following monoclonal antibodies: CD45RO, CD25, CD69, CD62L, CD28, and HLA-DR (Immunotech, a Beckman Coulter Company). Erythrocytes were subsequently lysed with FACSTM™ lysing solution (Becton-Dickinson Immunocytometry System, San Jose, CA, USA). After a final wash, the cells were fixed in PBS containing 1% paraformaldehyde. Alternatively, for detection of intracellular FoxP3, 80 μl of whole blood was incubated for 15 min at room temperature with anti-CD3 and CD4 monoclonal antibodies (Becton Dickinson, Mountain View, Calif.), after 15 min the cells were washed twice with PBS-BSA-Saponin 0.2% and blocked with AB serum 1% for 5 min. After that, the cells were incubated with anti-FoxP3 for 30 min. The cells were washed and fixed. Analyses were performed using FACSAria II (Becton Dickinson, Mountain View, Calif.) and the software FlowJo 7.5 (Tree stars, San Diego). At least 10^5 events were analyzed per sample.

**Detection of intracellular IFN-γ**

PBMCs (2 x 10^6 cells/well) were cultured in RPMI 1640 (Sigma Chemical Co., St. Louis, MO) medium, supplemented with 25 mM of HEPEs, 2 mM of L-glutamine, 1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 U/mL of penicillin, 100 g/mL of streptomycin and
10% pooled human AB serum (Sigma), and plated in triplicate in 96-well U-bottom plates (Costar, Cambridge, MA), then incubated for 4 h at 37°C under 5% CO2. Next, monensin and brefeldin (3 μg/ml) in AB serum (10%) (Sigma) were added to each culture, and then reincubated for 16 h. The cells were then washed with PBS-BSA-PFA-azide (2 mL) and stained with monoclonal anti-CD4, and antiCD3 antibodies for 15 min at 4°C. The cells were then fixed in PBS containing 4% paraformaldehyde 200 μl for 20 min at room temperature, followed by two washing cycles with 0.1% PBS-BSA-Saponin. Positive control cells were cultured with 2 μg/ml phytohaemagglutinin (PHA) (Sigma). To conduct intracellular cytokine staining, the cells were then reincubated for 30 min with anti-IFN-γ-PE monoclonal antibodies or isotype controls, then washed with 0.1% PBS-BSA-Saponin, and washed again with PBS-BSA-PFA-azide. Cells were analyzed using a FACSsort flow cytometer and data was interpreted by Cellquest software (Becton Dickinson, Mountain View, Calif.).

**Proviral load**

PBMCs were obtained from EDTA blood using density gradient centrifugation and cryopreserved until use. DNA was extracted using a DNA extraction system (Qiagen, Hilden, Germany). HTLV-1 proviral load was quantified using a real-time TaqMan polymerase chain reaction (PCR) method, as previously described [25]. Briefly, SK110/SK111 primers were used to amplify a 186 bp fragment of the pol gene and dual TaqMan probe (50-FAM/ 50 VIC and 30-TAMRA) was attached at 4,829–4,858 bp of the HTLV-1 reference sequence (HTLVATK). Albumin DNA was used as an endogenous reference and HTLV-1 PVL was calculated as the ratio of [(HTLV-1 DNA average copy number)/(albumin DNA average copy number)] × 2 × 10^6 and expressed as the number of HTLV-1 copies per 10^6 PBMCs.

**Statistical analyses**

Data are expressed as median and interquartile range (25th percentile and the 75th percentile). Kruskal–Wallis test with the Bonferroni-Dunn multiple comparisons. The level of significance was set at P < 0.05.

---

**Figure 1** Activation profile of CD4+ (A) and CD8+ (B) T-lymphocytes from asymptomatic HTLV-1-infected individuals. Flow cytometry was performed using fresh whole blood samples. Data represents median and interquartile range of 20 asymptomatic HTLV-1 infected individuals grouped according to HTLV-1 PVL expressed as ≥1% (10 individuals) and <1% of infected cells (10 individuals) and 10 healthy donors (HD). Kruskal–Wallis test with the Bonferroni-Dunn multiple comparisons. The level of significance was set at P < 0.05.
non-parametric analysis of variance with the Bonferroni-Dunn multiple comparison tests was used to compare healthy donors, asymptomatic with PVL $\geq 1\%$ and $< 1\%$ of infected cells groups. The Fisher exact chi-square test was used to compare lymphoproliferation frequencies. The correlations were performed by Spearman correlation test. Significant differences were considered for $p < 0.05$. GraphPad Prism 5 (La Jolla, CA) Software was used for all statistical analyses.

Results
The median PVL in all HTLV-1-infected carriers was 1.5% of infected cells (IQR, interquartile range 0.12-5.3%), 60% of them had PVL higher than 1% of infected cells. There were no statistically significant differences in markers of cellular activation of CD4$^+$ T-lymphocytes between PVL $\geq 1\%$ and $< 1\%$ HTLV-1-infected groups (Figure 1A). The proportion of both CD4$^+$CD25$^+$CD45RO$^+$ and CD4$^+$HLA-DR$^+$ T-cells from infected individuals with PVL $\geq 1\%$ was higher than healthy donors (13.2% vs 4.0%, $p = 0.02$; 18.0% vs. 8.3%, $p = 0.02$, respectively).

Moreover, the frequency of CD4$^+$CD25$^+$CD45RO$^+$ T-cell subset was directly correlated to the HTLV-1 PVL ($R = 0.7$, $p = 0.003$).

Concerning the CD8$^+$ T-cell subset (Figure 1B), the frequency of CD8$^+$CD28$^+$ cells was similar between PLV $\geq 1\%$ and $< 1\%$ groups. A lower frequency of cells expressing CD28 was observed in HTLV-1-infected individuals with PVL $< 1\%$ (median 64%, IQR 51-75%) compared to healthy donors (median 91%, IQR 71-98%) ($p = 0.01$).

A higher frequency of CD4$^+$IFN-$\gamma^+$ T-cells (4.5%) was observed in the PVL $\geq 1\%$ group, compared to healthy donors (1%) ($P = 0.01$), while frequencies of CD8$^+$IFN-$\gamma^+$ T-cells was similar for HTLV-1 infected groups and healthy donors (Figure 2). The frequencies of individuals with spontaneous lymphocyte proliferation in the group PVL $\geq 1\%$ (72%, 13 out of 18) was similar to that observed in the group PVL $< 1\%$ (64%, 7 out of 11) ($P = 0.69$). There was no difference between the magnitudes of proliferation between both groups. However, considering only patients that presented spontaneous proliferation, a positive correlation between PVL and magnitude proliferation was observed ($R = 0.7$; $P = 0.007$). The frequency of CD4$^+$FoxP3$^+$ T-cells was higher among individuals infected with HTLV-1, compared to healthy donors ($P = 0.01$) (Figure 3).

Discussion
The present study demonstrated that the HTLV-1 PVL is directly associated with immune system activation in asymptomatic carriers. A higher frequency of activated CD4$^+$ T-lymphocytes expressing CD25 + CD45RO+, HLA-DR$^+$ and of cells producing IFN-$\gamma$ were mostly observed in the subgroup of infected individuals with PVL $\geq 1\%$ of infected cells, compared to healthy donors. A cut-off value of 1% for PVL was chosen to distinguish between low and elevated levels in accordance with the literature review by Golçalves et al. [20], which considered $< 1\%$ as low, between 1-5% as intermediate and >5% as high. Although the median PVL was determined to be 1.5%, a highly variable percentage of infected cells was observed in included individuals (interquartile range of 0.12-5.3%). When the cut-off of 1.5 was selected, no significant differences were observed between groups. The Mann-Whitney U-test was used to compare healthy donors (HD, n = 10) and asymptomatic HTLV-1-infected individuals (ASS, n = 15). ASS individuals had PVL $< 1\%$ infected cells, except one 26% of infected cells. *$p = 0.02$.
The memory CD4+CD45RO+ T-cells are the main target for HTLV-1 infection and are preferentially involved in the spontaneous proliferation. It is estimated that the rate of proliferation of memory T-cells induced by the virus reach 3% per day [33].

The immune response is partially effective maintaining PVL stable over time, probably due to the cytotoxic response mediated by CD8+ T-lymphocytes that destroys infected cells. However, the immune response is unable to clear the infection [33-35]. Regarding the subpopulation of CD8+ T cells, our study showed a reduced expression of CD28 in the HTLV-1-infected group, although statistically significant only in the subgroup with PVL <1% compared to healthy donors.

Low expression of CD28 on CD8+ T-subset has been described primarily in patients with HAM/TSP [36]. Conversely, in other chronic or persistent infections such as schistosomiasis, Chagas’ disease, and HIV infection a decrease of CD28 expression is also found [35,37,38].

CD28 is a costimulatory molecule expressed on T lymphocytes that interacts with natural ligands CD80 and CD86 located on antigen-presenting cells that result in cell activation. The reduction on CD28 expression found herein may represent a deactivation pathway of the immune system.

On the other hand, a fivefold increase in the frequency of regulatory T cells (CD4+FoxP3+) was observed in the group infected with HTLV-1, compared to healthy donors. These results were similar to those obtained by other studies [17,39] indicating that the virus drives an expansion of regulatory T-cells. This expansion however would not be sufficient to control cell activation induced by the HTLV-1 infection. However, it has been reported that Forkhead box P3 (FOXP3) protein may be transiently expressed on activated T CD4+ cells and its expression does not necessarily convey regulatory function [40,41]. In the present study, we were unable to evaluate the function of these cells.

**Conclusions**

In summary, the results presented herein indicate that intermediate HTLV-1 PVL is associated with activation of both CD4+ and CD8+ T-lymphocytes in asymptomatic individuals. Prospective studies should be conducted to evaluate whether asymptomatic individuals with higher PVL and high immune activation are more prone to developing HTLV-1-associated diseases. The HTLV-1 PVL may be a relevant marker in monitoring asymptomatic individuals.

**Competing interests**

There is no conflicting financial interest.

**Authors’ contributions**

RC, study design, performed experiments, data collection and data analysis, first author. MFRG, study design, project leader, 1st senior author. ABK, performed experiments, data collection and data analysis, co-author. VNO, performed experiments, data collection and data analysis, co-author. BGC, manuscript completion, 2nd senior author. REM, study design, data collection and data analysis, co-ordination of manuscript review by co-authors. All authors read and approved the final manuscript.

**Acknowledgments**

This study was supported by the Fundação de Amparo à Pesquisa da Bahia (FAPESB). We thank Dr. Raymond Césarie for providing HTLV/Albumina clones and M. Andrei K. Walter for his assistance in English revision.

Received: 19 March 2014 Accepted: 18 August 2014
Published: 22 August 2014

**References**

1. Poinz B, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77(12):7415–7419.

2. Geissain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3:398.
Isolation and characterization of HTLV-I versus HTLV-II. human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011, 83(7):1269–1274.

Primo JR, Bites C, Oliveira Mde F, Moreno-Carvalho O, Machado M, Bittencourt AC: Infective dermatitis and human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence. Clin Infect Dis 2005, 41(4):535–541.

Castaño-Lim Vargas C, Grassi MF, Boa-Sorte N, Rathams-Pinheiro RH, Olavarria VN, de Almeida Kuschewsky R, Galvao-Castro B: Keratoconjunctivitis sicca of human T cell lymphotropic virus type 1 (HTLV-I) infected individuals is associated with high levels of HTLV-1 proviral load. J Clin Virol 2011, 52(3):177–180.

Dehee A, Cesare R, Desire N, Lezin A, Bourdonne O, Bera O, Plumyelle Y, Smadja D, Nicolas J: Quantitation of HTLV-I proviral load by a TaqMan real-time PCR assay. J Virol Methods 2002, 102(1):237–251.

Popovic M, Flomenberg N, Volkman DJ, Mann D, Fauci AS, Dupont B, Gallo RC: Alteration of T-cell functions by infection with HTLV-I or HTLV-II. Science 1984, 226(4673):459–462.

Asnin N, Jacobsson S, Leist T, Willimann T: Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol 1999, 163(7):4004–4007.

Carvalho EM, Bacellar O, Porto AF, Braga S, Galvao-Castro B, Neiva F: Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type-1 infected blood donors. J Acquir Immune Defic Syndr 2001, 27(1):1–6.

Nishiyama Y, Nakamura T, Ichinose K, Shibane S, Tsujino A, Goto H, Furuya T, Nagatoki S: Increased production of inflammatory cytokines in cultured CD4+ cells from patients with HTLV-I-associated myelopathy. Tohoku J Exp Med 1996, 179(4):227–233.

Primo L, Siqueira I, Nascimento MC, Oliveira MF, Farre L, Carvalho EM, Bittencourt AL: High-level HTLV-1 proviral load, a marker for HTLV-I associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res 2009, 42(8):761–764.

Itoh Y, Minato S, Kira J, Goto I, Sato H, Okochi K, Yamamoto N: Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 1998, 50(8):1302–1307.

Matsumoto M, Sugimoto M, Nakashima H, Imamura F, Kawanoo O, Uyama E, Takatsu K, Araki S: Spontaneous T cell proliferation and release of soluble interleukin-2 receptors in patients with HTLV-I-associated myelopathy. Am J Trop Med Hyg 1990, 42(4):365–373.

Asquith B, Zhang Y, Mosley AJ, de Lara CM, Wallace DL, Worth A, Kaftantzi L, Itoh Y, Minato S, Kira J, Goto I, Sato H, Okochi K, Yamamoto N: Increased risk of HIV disease progression among individuals with high levels of HTLV-I proviral load. J Acquir Immune Defic Syndr 2008, 49(5):570–577.
39. Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M: HTLV-1 modulates the frequency and phenotype of FoxP3+ CD4+ T cells in virus-infected individuals. Retrovirology 2012, 9:46.

40. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007, 19(4):345–354.

41. Kmieciak M, Gowda M, Graham L, Godder K, Bear HD, Marincola FM, Manjili MH: Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 2009, 7:89.

doi:10.1186/1471-2334-14-453
Cite this article as: Coutinho et al: Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers. BMC Infectious Diseases 2014 14:453.